To understand how GLS2 suppression metabolically supports the EMT, we overexpressed GLS2 in the SUM159 breast cancer cell line, a line that has mesenchymal characteristics; experiments were also performed with the same cells expressing control vector (Figure 3A). This evidence concerns the gene GLS2 and breast carcinoma.